<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250307212411&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250307212411&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 08 Mar 2025 02:24:12 +0000</lastbuilddate>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Plaque erosion risk and JAK2 V617F variant</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: JAK2 V617F linked to a high risk of erosion, an association to which enhanced neutrophil activation may contribute.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf114. doi: 10.1093/eurheartj/ehaf114. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Clonal haematopoiesis of indeterminate potential (CHIP) can increase the risk of myocardial infarction (MI). Among various CHIP mutations, JAK2 V617F substantially elevated this risk. However, the specific associations between JAK2 V617F and two mechanisms of MI, plaque erosion and plaque rupture, remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Case-control studies investigated these associations. A total of 728 erosion cases, 919 rupture cases, and 804 controls were included from our centre. Digital-drop polymerase chain reaction was performed on these individuals to identify the presence of JAK2 V617F. Previous experimental work has implicated neutrophils in the pathogenesis of erosion in the presence of this mutation. Thus, single-cell RNA sequencing of neutrophils from both JAK2 V617F carriers and healthy donors was performed to seek the potential mechanisms responsible for erosion associated with JAK2 V617F.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the participants, 26 (3.57%) erosion patients, 7 (.76%) rupture patients, and 3 (.37%) controls were identified as JAK2 V617F carriers with a variant allele frequency (VAF) ≥1%. The carriers among the erosion patients exhibited higher platelet counts and lower glycated haemoglobin and blood lipid levels. Logistic regression analysis, considering erosion or rupture as separate cases, revealed that JAK2 V617F carriers with a VAF ≥1% showed a significant association with erosion [odds ratio (OR) 16.246, 95% confidence interval (CI) 4.624-57.080, P &lt; .0001], but not with rupture (OR 1.677, 95% CI .379-7.415, P = .495). Single-cell RNA-sequencing data indicated that neutrophils from JAK2 V617F carriers displayed augmented expression levels of genes and gene sets associated with activation, adhesion, migration, and granule secretion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: JAK2 V617F linked to a high risk of erosion, an association to which enhanced neutrophil activation may contribute.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053703</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf114>10.1093/eurheartj/ehaf114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053703</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Shengfang Wang</dc:creator>
<dc:creator>Xing Luo</dc:creator>
<dc:creator>Sining Hu</dc:creator>
<dc:creator>Chen Zhao</dc:creator>
<dc:creator>Qianhui Sun</dc:creator>
<dc:creator>Ming Zeng</dc:creator>
<dc:creator>Xiaoyi Bao</dc:creator>
<dc:creator>Yini Wang</dc:creator>
<dc:creator>Fangfang Wu</dc:creator>
<dc:creator>Yeqiu Yang</dc:creator>
<dc:creator>Ying Lv</dc:creator>
<dc:creator>Xiaoxuan Bai</dc:creator>
<dc:creator>Wei Hao</dc:creator>
<dc:creator>Minghao Liu</dc:creator>
<dc:creator>Boling Yi</dc:creator>
<dc:creator>Yuwu Chen</dc:creator>
<dc:creator>Wei Meng</dc:creator>
<dc:creator>Ji Li</dc:creator>
<dc:creator>Man Li</dc:creator>
<dc:creator>Jianxin Huang</dc:creator>
<dc:creator>Tianyu Wu</dc:creator>
<dc:creator>Yipin Zhao</dc:creator>
<dc:creator>Zhulin Zhang</dc:creator>
<dc:creator>Jian An</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Haibo Jia</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plaque erosion risk and JAK2 V617F variant</dc:title>
<dc:identifier>pmid:40053703</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf114</dc:identifier>
</item>
<item>
<title>Gender-specific associations and circulating proteins in myocardial infarction: potential causal relationships</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf111. doi: 10.1093/eurheartj/ehaf111. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053702</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf111>10.1093/eurheartj/ehaf111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053702</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Yi Xu</dc:creator>
<dc:creator>Tianpu Feng</dc:creator>
<dc:creator>Yuanyuan Huang</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gender-specific associations and circulating proteins in myocardial infarction: potential causal relationships</dc:title>
<dc:identifier>pmid:40053702</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf111</dc:identifier>
</item>
<item>
<title>A novel percutaneous technique for closing anomalous left coronary artery origin from the pulmonary artery using the Fustar™ Steerable Introducer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf090. doi: 10.1093/eurheartj/ehaf090. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053696</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf090>10.1093/eurheartj/ehaf090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053696</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Shubo Song</dc:creator>
<dc:creator>Liyun Zhao</dc:creator>
<dc:creator>Taibing Fan</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A novel percutaneous technique for closing anomalous left coronary artery origin from the pulmonary artery using the Fustar™ Steerable Introducer</dc:title>
<dc:identifier>pmid:40053696</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf090</dc:identifier>
</item>
<item>
<title>Circulating proteins and incident myocardial infarction: appraising sex-specific differences and causality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053693/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf113. doi: 10.1093/eurheartj/ehaf113. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053693/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053693</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf113>10.1093/eurheartj/ehaf113</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053693</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Olga E Titova</dc:creator>
<dc:creator>Shuai Yuan</dc:creator>
<dc:creator>Liisa Byberg</dc:creator>
<dc:creator>John A Baron</dc:creator>
<dc:creator>Lars Lind</dc:creator>
<dc:creator>Karl Michaëlsson</dc:creator>
<dc:creator>Susanna C Larsson</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Circulating proteins and incident myocardial infarction: appraising sex-specific differences and causality</dc:title>
<dc:identifier>pmid:40053693</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf113</dc:identifier>
</item>
<item>
<title>Possible perspectives for cardiovascular events following coronavirus disease 2019 vaccination</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053691/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf112. doi: 10.1093/eurheartj/ehaf112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053691/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053691</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf112>10.1093/eurheartj/ehaf112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053691</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Xue-Yan Gong</dc:creator>
<dc:creator>James Cheng-Chung Wei</dc:creator>
<dc:creator>Li-Yun Zhang</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Possible perspectives for cardiovascular events following coronavirus disease 2019 vaccination</dc:title>
<dc:identifier>pmid:40053691</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf112</dc:identifier>
</item>
<item>
<title>Focus on coronary atherosclerosis in athletes, angina with non-obstructive coronary arteries, mechanisms of acute vascular syndromes, and Marfan syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40053441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7;46(10):877-881. doi: 10.1093/eurheartj/ehaf055.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40053441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40053441</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf055>10.1093/eurheartj/ehaf055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40053441</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on coronary atherosclerosis in athletes, angina with non-obstructive coronary arteries, mechanisms of acute vascular syndromes, and Marfan syndrome</dc:title>
<dc:identifier>pmid:40053441</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf055</dc:identifier>
</item>
<item>
<title>Pushing boundaries: the uncharted territory of managing a 110-year-old patient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40052840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf030. doi: 10.1093/eurheartj/ehaf030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40052840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40052840</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf030>10.1093/eurheartj/ehaf030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40052840</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pushing boundaries: the uncharted territory of managing a 110-year-old patient</dc:title>
<dc:identifier>pmid:40052840</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf030</dc:identifier>
</item>
<item>
<title>Advancing equitable healthy longevity in South and Southeast Asia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40052839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf051. doi: 10.1093/eurheartj/ehaf051. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40052839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40052839</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf051>10.1093/eurheartj/ehaf051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40052839</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Raaj Kishore Biswas</dc:creator>
<dc:creator>Nicholas A Koemel</dc:creator>
<dc:creator>Luigi Fontana</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Advancing equitable healthy longevity in South and Southeast Asia</dc:title>
<dc:identifier>pmid:40052839</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf051</dc:identifier>
</item>
<item>
<title>An update on the European Society of Cardiology Council of Cardio-Oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40052835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf052. doi: 10.1093/eurheartj/ehaf052. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40052835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40052835</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf052>10.1093/eurheartj/ehaf052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40052835</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>An update on the European Society of Cardiology Council of Cardio-Oncology</dc:title>
<dc:identifier>pmid:40052835</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf052</dc:identifier>
</item>
<item>
<title>SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40052832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehae751. doi: 10.1093/eurheartj/ehae751. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40052832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40052832</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae751>10.1093/eurheartj/ehae751</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40052832</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Franz H Messerli</dc:creator>
<dc:creator>Renate Schoenenberger-Berzins</dc:creator>
<dc:creator>Michel Burnier</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension</dc:title>
<dc:identifier>pmid:40052832</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae751</dc:identifier>
</item>
<item>
<title>Clinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40052272/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We demonstrate that real-world implementation of the OCS for DBD donors (using predominantly a dedicated recovery team) is associated with expanded donor criteria, longer transport distance, and excellent posttransplantation outcomes. In OCS-DCD donors, outcomes parallel those of donors recovered with NRP-DCD and compare favorably with DBD donor organs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 7. doi: 10.1161/CIRCULATIONAHA.124.071743. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A preservation system, the Organ Care System (OCS; TransMedics) uses normothermic pulsatile perfusion during organ transport for heart transplantation. This system has demonstrated favorable outcomes in hearts recovered from extended-criteria donors after brain death (DBD) and donors after circulatory death (DCD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The OCS Heart Perfusion Registry collects data on US heart transplantations using the OCS, static cold storage (SCS), or thoracoabdominal normothermic regional perfusion (NRP) recovered from DBD or DCD donors. We analyzed donor and recipient characteristics and posttransplantation outcomes in patients transplanted with OCS donor hearts (either DBD or DCD) compared with SCS hearts and OCS hearts from DCD donors compared with those recovered with NRP followed by SCS. Propensity score matching was used in survival analyses to adjust for differences among recipient characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between 2021 and 2023, 3225 consecutive heart transplantations enrolled from 56 centers were analyzed in the Heart Perfusion Registry. The OCS was used in 854 of 3225 heart transplantations (26.4%), among which 340 (39.8%) were DBD and 514 (60.2%) were DCD donors, whereas 2174 DBD donors were recovered with SCS and another 197 DCD donors with NRP techniques. The OCS-DBD group experienced a greater number of organ offer refusals before final acceptance (13 versus 6; Wilcoxon rank sum, <i>P</i>&lt;0.001) and a longer transport distance (667 miles versus 232 miles; Wilcoxon rank sum, <i>P</i>&lt;0.001) compared with SCS-DBD. Survival at 12 months was similar between the 2 groups (89.9% for OCS-DBD versus 90.6% for SCS-DBD; marginal Cox model, <i>P</i>=0.54). Among the OCS-DCD and SCS-DBD groups, survival at 12 months was also similar (91.0% versus 92.5%, respectively; marginal Cox model, <i>P</i>=0.32). The OCS-DCD and NRP-DCD groups demonstrated similar survival (91.0% versus 91.7%, respectively; log rank, <i>P</i>=0.63), although the transport distance was longer in OCS-DCD compared with DCD with NRP followed by SCS (400 miles versus 223 miles; Wilcoxon rank sum, <i>P</i>&lt;0.001). By 2023, 90% of all OCS donor management and recovery was performed with dedicated organ recovery teams.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We demonstrate that real-world implementation of the OCS for DBD donors (using predominantly a dedicated recovery team) is associated with expanded donor criteria, longer transport distance, and excellent posttransplantation outcomes. In OCS-DCD donors, outcomes parallel those of donors recovered with NRP-DCD and compare favorably with DBD donor organs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40052272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40052272</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071743>10.1161/CIRCULATIONAHA.124.071743</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40052272</guid>
<pubDate>Fri, 07 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Josef Stehlik</dc:creator>
<dc:creator>Maryjane A Farr</dc:creator>
<dc:creator>Mandeep R Mehra</dc:creator>
<dc:creator>Jacob N Schroder</dc:creator>
<dc:creator>David A D'Alessandro</dc:creator>
<dc:creator>Jay D Pal</dc:creator>
<dc:creator>Mauricio A Villavicencio</dc:creator>
<dc:creator>Peter J Gruber</dc:creator>
<dc:creator>Gregory S Couper</dc:creator>
<dc:creator>Yasuhiro Shudo</dc:creator>
<dc:creator>Parag C Patel</dc:creator>
<dc:creator>Mani A Daneshmand</dc:creator>
<dc:creator>Liviu Klein</dc:creator>
<dc:creator>Ashish S Shah</dc:creator>
<dc:creator>Eric R Skipper</dc:creator>
<dc:creator>Fardad Esmailian</dc:creator>
<dc:creator>Daniel Goldstein</dc:creator>
<dc:creator>Suguru Ohira</dc:creator>
<dc:creator>Lucian Lozonschi</dc:creator>
<dc:creator>David J Kaczorowski</dc:creator>
<dc:creator>Koji Takeda</dc:creator>
<dc:creator>Rajasekhar S R Malyala</dc:creator>
<dc:creator>Jonathan W Haft</dc:creator>
<dc:creator>Dan M Meyer</dc:creator>
<dc:creator>Benjamin C Sun</dc:creator>
<dc:creator>Victor Pretorius</dc:creator>
<dc:creator>Arman Kilic</dc:creator>
<dc:creator>Anelechi C Anyanwu</dc:creator>
<dc:creator>Celeste T Williams</dc:creator>
<dc:creator>Duc T Pham</dc:creator>
<dc:creator>Masashi Kai</dc:creator>
<dc:creator>Nasir Z Sulemanjee</dc:creator>
<dc:creator>Akinobu Itoh</dc:creator>
<dc:creator>Masaki Funamoto</dc:creator>
<dc:creator>Christopher T Salerno</dc:creator>
<dc:creator>John S Ikonomidis</dc:creator>
<dc:creator>Lucian A Durham</dc:creator>
<dc:creator>Andrew Shaffer</dc:creator>
<dc:creator>Xiang Zhou</dc:creator>
<dc:creator>Farhan Zafar</dc:creator>
<dc:creator>Sean P Pinney</dc:creator>
<dc:creator>Carmelo A Milano</dc:creator>
<dc:date>2025-03-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry</dc:title>
<dc:identifier>pmid:40052272</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071743</dc:identifier>
</item>
<item>
<title>The Australian-New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40049585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The findings support the hypothesis that SCAD is primarily caused by intramural bleeding, with a harmful association of more potent antiplatelet therapy and anticoagulation with adverse cardiovascular outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 7:ehaf097. doi: 10.1093/eurheartj/ehaf097. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndrome (ACS). Recent data suggest a harmful association of dual antiplatelet therapy compared with single antiplatelet therapy following SCAD. This study investigated independent predictors of major adverse cardiovascular events (MACEs) and recurrence in patients with SCAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This multicentre cohort study involving 23 Australian and New Zealand sites included patients aged ≥18 years with an ACS due to SCAD confirmed on core laboratory adjudication. Multivariable Cox proportional hazard models analysed predictors for the primary MACE outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 586 patients, 505 (150 prospective, 355 retrospective) with SCAD confirmed by core laboratory adjudication, mean age was 52.2 ± 10.6 years, 88.6% were female, and 74.5% were Caucasian. At long-term follow-up (median 21 months), MACE and SCAD recurrence occurred in 8.6% and 3.6% of patients, respectively. Oral anticoagulation on discharge [adjusted hazard ratio (aHR) 3.8, 95% confidence interval (CI) 1.6-9.3, P = .003], ticagrelor combined with aspirin (aHR 1.8, 95% CI 1.04-3.2, P = .037), fibromuscular dysplasia (aHR 2.2, 95% CI 1.05-4.5, P = .037), and history of stroke (aHR 3.8, 95% CI 1.2-12.2, P = .03) were independently associated with higher MACE. Fibromuscular dysplasia (aHR 3.9, 95% CI 1.5-26.5, P = .01), ticagrelor combined with aspirin (aHR 2.6, 95% CI 2.1-5.3, P = .01), and history of stroke (aHR 6.2, 95% CI 1.8-9.5, P = .01) were also associated with higher SCAD recurrence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings support the hypothesis that SCAD is primarily caused by intramural bleeding, with a harmful association of more potent antiplatelet therapy and anticoagulation with adverse cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40049585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40049585</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf097>10.1093/eurheartj/ehaf097</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40049585</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Quan M Dang</dc:creator>
<dc:creator>Peter J Psaltis</dc:creator>
<dc:creator>Sonya Burgess</dc:creator>
<dc:creator>Jaya Chandrasekhar</dc:creator>
<dc:creator>Swati Mukherjee</dc:creator>
<dc:creator>Leonard Kritharides</dc:creator>
<dc:creator>Nigel Jepson</dc:creator>
<dc:creator>Sarah Fairley</dc:creator>
<dc:creator>Abdul Ihdayhid</dc:creator>
<dc:creator>Jamie Layland</dc:creator>
<dc:creator>Richard Szirt</dc:creator>
<dc:creator>Seif El-Jack</dc:creator>
<dc:creator>Aniket Puri</dc:creator>
<dc:creator>Esther Davis</dc:creator>
<dc:creator>Imran Shiekh</dc:creator>
<dc:creator>Ruth Arnold</dc:creator>
<dc:creator>Monique Watts</dc:creator>
<dc:creator>Jessica A Marathe</dc:creator>
<dc:creator>Rohan Bhagwandeen</dc:creator>
<dc:creator>Edwina Wing-Lun</dc:creator>
<dc:creator>Ravinay Bhindi</dc:creator>
<dc:creator>Tom Ford</dc:creator>
<dc:creator>Sidney Lo</dc:creator>
<dc:creator>Simone Marschner</dc:creator>
<dc:creator>Sarah Zaman</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Australian-New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence</dc:title>
<dc:identifier>pmid:40049585</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf097</dc:identifier>
</item>
<item>
<title>In-cell structure and snapshots of copia retrotransposons in intact tissue by cryoelectron tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40049165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>Long terminal repeat (LTR) retrotransposons belong to the transposable elements (TEs), autonomously replicating genetic elements that integrate into the host's genome. Among animals, Drosophila melanogaster serves as an important model organism for TE research and contains several LTR retrotransposons, including the Ty1-copia family, which is evolutionarily related to retroviruses and forms virus-like particles (VLPs). In this study, we use cryo-focused ion beam (FIB) milling and lift-out...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 3:S0092-8674(25)00159-X. doi: 10.1016/j.cell.2025.02.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Long terminal repeat (LTR) retrotransposons belong to the transposable elements (TEs), autonomously replicating genetic elements that integrate into the host's genome. Among animals, Drosophila melanogaster serves as an important model organism for TE research and contains several LTR retrotransposons, including the Ty1-copia family, which is evolutionarily related to retroviruses and forms virus-like particles (VLPs). In this study, we use cryo-focused ion beam (FIB) milling and lift-out approaches to visualize copia VLPs in ovarian cells and intact egg chambers, resolving the in situ copia capsid structure to 7.7 Å resolution by cryoelectron tomography (cryo-ET). Although cytoplasmic copia VLPs vary in size, nuclear VLPs are homogeneous and form densely packed clusters, supporting a model in which nuclear import acts as a size selector. Analyzing flies deficient in the TE-suppressing PIWI-interacting RNA (piRNA) pathway, we observe copia's translocation into the nucleus during spermatogenesis. Our findings provide insights into the replication cycle and cellular structural biology of an active LTR retrotransposon.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40049165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40049165</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.003>10.1016/j.cell.2025.02.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40049165</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Sven Klumpe</dc:creator>
<dc:creator>Kirsten A Senti</dc:creator>
<dc:creator>Florian Beck</dc:creator>
<dc:creator>Jenny Sachweh</dc:creator>
<dc:creator>Bernhard Hampoelz</dc:creator>
<dc:creator>Paolo Ronchi</dc:creator>
<dc:creator>Viola Oorschot</dc:creator>
<dc:creator>Marlene Brandstetter</dc:creator>
<dc:creator>Assa Yeroslaviz</dc:creator>
<dc:creator>John A G Briggs</dc:creator>
<dc:creator>Julius Brennecke</dc:creator>
<dc:creator>Martin Beck</dc:creator>
<dc:creator>Jürgen M Plitzko</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>In-cell structure and snapshots of copia retrotransposons in intact tissue by cryoelectron tomography</dc:title>
<dc:identifier>pmid:40049165</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.003</dc:identifier>
</item>
<item>
<title>CXCL12 drives natural variation in coronary artery anatomy across diverse populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40049164/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>Coronary arteries have a specific branching pattern crucial for oxygenating heart muscle. Among humans, there is natural variation in coronary anatomy with respect to perfusion of the inferior/posterior left heart, which can branch from either the right arterial tree, the left, or both-a phenotype known as coronary dominance. Using angiographic data for >;60,000 US veterans of diverse ancestry, we conducted a genome-wide association study of coronary dominance, revealing moderate heritability and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 3:S0092-8674(25)00161-8. doi: 10.1016/j.cell.2025.02.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronary arteries have a specific branching pattern crucial for oxygenating heart muscle. Among humans, there is natural variation in coronary anatomy with respect to perfusion of the inferior/posterior left heart, which can branch from either the right arterial tree, the left, or both-a phenotype known as coronary dominance. Using angiographic data for >;60,000 US veterans of diverse ancestry, we conducted a genome-wide association study of coronary dominance, revealing moderate heritability and identifying ten significant loci. The strongest association occurred near CXCL12 in both European- and African-ancestry cohorts, with downstream analyses implicating effects on CXCL12 expression. We show that CXCL12 is expressed in human fetal hearts at the time dominance is established. Reducing Cxcl12 in mice altered coronary dominance and caused septal arteries to develop away from Cxcl12 expression domains. These findings indicate that CXCL12 patterns human coronary arteries, paving the way for "medical revascularization" through targeting developmental pathways.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40049164/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40049164</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.005>10.1016/j.cell.2025.02.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40049164</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Pamela E Rios Coronado</dc:creator>
<dc:creator>Jiayan Zhou</dc:creator>
<dc:creator>Xiaochen Fan</dc:creator>
<dc:creator>Daniela Zanetti</dc:creator>
<dc:creator>Jeffrey A Naftaly</dc:creator>
<dc:creator>Pratima Prabala</dc:creator>
<dc:creator>Azalia M Martínez Jaimes</dc:creator>
<dc:creator>Elie N Farah</dc:creator>
<dc:creator>Soumya Kundu</dc:creator>
<dc:creator>Salil S Deshpande</dc:creator>
<dc:creator>Ivy Evergreen</dc:creator>
<dc:creator>Pik Fang Kho</dc:creator>
<dc:creator>Qixuan Ma</dc:creator>
<dc:creator>Austin T Hilliard</dc:creator>
<dc:creator>Sarah Abramowitz</dc:creator>
<dc:creator>Saiju Pyarajan</dc:creator>
<dc:creator>Daniel Dochtermann</dc:creator>
<dc:creator>Million Veteran Program</dc:creator>
<dc:creator>Scott M Damrauer</dc:creator>
<dc:creator>Kyong-Mi Chang</dc:creator>
<dc:creator>Michael G Levin</dc:creator>
<dc:creator>Virginia D Winn</dc:creator>
<dc:creator>Anca M Paşca</dc:creator>
<dc:creator>Mary E Plomondon</dc:creator>
<dc:creator>Stephen W Waldo</dc:creator>
<dc:creator>Philip S Tsao</dc:creator>
<dc:creator>Anshul Kundaje</dc:creator>
<dc:creator>Neil C Chi</dc:creator>
<dc:creator>Shoa L Clarke</dc:creator>
<dc:creator>Kristy Red-Horse</dc:creator>
<dc:creator>Themistocles L Assimes</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>CXCL12 drives natural variation in coronary artery anatomy across diverse populations</dc:title>
<dc:identifier>pmid:40049164</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.005</dc:identifier>
</item>
<item>
<title>Common and divergent cellular aetiologies underlying hypoplastic left heart syndrome and hypoplastic right heart syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40048662/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 6:ehaf121. doi: 10.1093/eurheartj/ehaf121. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40048662/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40048662</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf121>10.1093/eurheartj/ehaf121</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40048662</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Yang Yu</dc:creator>
<dc:creator>Cankun Wang</dc:creator>
<dc:creator>Shiqiao Ye</dc:creator>
<dc:creator>Hannah Qin</dc:creator>
<dc:creator>Matthew Alonzo</dc:creator>
<dc:creator>Angela Onorato</dc:creator>
<dc:creator>Aaron Argall</dc:creator>
<dc:creator>Karen Texter</dc:creator>
<dc:creator>Qin Ma</dc:creator>
<dc:creator>Vidu Garg</dc:creator>
<dc:creator>Ming-Tao Zhao</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Common and divergent cellular aetiologies underlying hypoplastic left heart syndrome and hypoplastic right heart syndrome</dc:title>
<dc:identifier>pmid:40048662</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf121</dc:identifier>
</item>
<item>
<title>Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40048661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with ischaemic cardiomyopathy receiving medical therapy in REVIVED-BCIS2 had better outcomes than those in STICHES, with or without CABG surgery. Further trials comparing CABG, PCI, and medical therapy in this population are warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 6:ehaf080. doi: 10.1093/eurheartj/ehaf080. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In the Surgical Treatment for Ischaemic Heart Failure Trial Extension Study (STICHES), coronary artery bypass grafting (CABG) improved outcomes of patients with ischaemic left ventricular dysfunction receiving medical therapy, whereas in the Revascularization for Ischaemia Ventricular Dysfunction trial (REVIVED-BCIS2), percutaneous coronary intervention (PCI) did not. The aim of this study was to explore differences in outcomes of participants treated with medical therapy alone in STICHES vs. REVIVED-BCIS2 and to assess the incremental benefit of CABG or PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pooled analysis of adjusted individual participant data from two multicentre randomized trials. All patients had left ventricular ejection fraction ≤35% and coronary artery disease and received medical therapy. Participants were randomized 1:1 to CABG (STICHES) or PCI (REVIVED-BCIS2). The primary outcome was the composite of all-cause death and hospitalization for heart failure over all available follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1912 participants (88% male, 76% white ethnicity) were included with 98.3% completeness of follow-up for the primary outcome. The median follow-up was 118 months in STICHES and 41 months in REVIVED-BCIS2. Those receiving medical therapy alone in REVIVED-BCIS2 had fewer primary outcome events than those receiving medical therapy alone in STICHES (adjusted hazard ratio 0.60, 95% confidence interval 0.48-0.74, P &lt; .001). Patients receiving PCI in REVIVED-BCIS2 were less likely to experience a primary outcome event than those receiving CABG in STICHES. Adjusted outcomes of patients treated with CABG in STICHES were worse than those receiving medical therapy alone in REVIVED-BCIS2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with ischaemic cardiomyopathy receiving medical therapy in REVIVED-BCIS2 had better outcomes than those in STICHES, with or without CABG surgery. Further trials comparing CABG, PCI, and medical therapy in this population are warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40048661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40048661</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf080>10.1093/eurheartj/ehaf080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40048661</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew Ryan</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Evangelos Kontopantelis</dc:creator>
<dc:creator>Matthew Dodd</dc:creator>
<dc:creator>Guangyu Tong</dc:creator>
<dc:creator>Guillaume Marquis-Gravel</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Tim Clayton</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:creator>Jean-Lucien Rouleau</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Divaka Perera</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis</dc:title>
<dc:identifier>pmid:40048661</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf080</dc:identifier>
</item>
<item>
<title>SLC31A1 loss depletes mitochondrial copper and promotes cardiac fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40048660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A novel epigenetic mechanism was demonstrated through which copper deficiency increases mitochondrial copper depletion and impairs CF. Findings provide new insights for the development of preventive measures for CF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 6:ehaf130. doi: 10.1093/eurheartj/ehaf130. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Metals serve as co-factors for a host of metalloenzymes involved in mitochondrial metabolic reprogramming. Modifications in metal homeostasis are linked to epigenetic mechanisms. However, the epigenetic mechanisms through which metal affects cardiac fibrosis (CF) remain poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The metal content of mouse heart samples was measured using inductively coupled plasma mass spectrometry. Cardiac fibroblast-specific MeCP2-deficient mice and control mice were treated with isoprenaline/angiotensin II to induce CF. AAV9 carrying POSTN promoter-driven small hairpin RNA targeting MeCP2, YTHDF1, or SLC31A1 and the copper-chelating agent tetrathiomolybdate were administered to investigate their vital roles in CF. Histological and biochemical analyses were performed to determine how YTHDF1/MeCP2 regulated SLC31A1 expression in CF. The reconstitution of SLC31A1 in YTHDF1/MeCP2-deficient cardiac fibroblasts and mouse hearts was performed to study its effect on mitochondrial copper depletion and fibrosis. Human heart tissues from atrial fibrillation patients were used to validate the findings.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Lower copper concentrations are accompanied by SLC31A1 down-regulation and mitochondrial copper depletion in CF. Fibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF. SLC31A1 inhibition due to increased MeCP2-recognized methylating CpG islands of SLC31A1 in the promoter region restrains its transcription. Conversely, MeCP2 knockdown rescued SLC31A1 expression, resulting in contradictory effects. MeCP2 up-regulation is associated with elevated m6A mRNA levels. Mechanistically, YTHDF1 recognizes target MeCP2 mRNA and induces its translation. In human heart tissues from atrial fibrillation patients, reduced copper concentrations and SLC31A1 expression, along with elevated levels of YTHDF1 and MeCP2, were observed. These changes were associated with mitochondrial copper depletion, enhanced glycolysis, and CF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A novel epigenetic mechanism was demonstrated through which copper deficiency increases mitochondrial copper depletion and impairs CF. Findings provide new insights for the development of preventive measures for CF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40048660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40048660</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf130>10.1093/eurheartj/ehaf130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40048660</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Bin Tu</dc:creator>
<dc:creator>Kai Song</dc:creator>
<dc:creator>Ze-Yu Zhou</dc:creator>
<dc:creator>Li-Chan Lin</dc:creator>
<dc:creator>Zhi-Yan Liu</dc:creator>
<dc:creator>He Sun</dc:creator>
<dc:creator>Yang Zhou</dc:creator>
<dc:creator>Ji-Ming Sha</dc:creator>
<dc:creator>Yan Shi</dc:creator>
<dc:creator>Jing-Jing Yang</dc:creator>
<dc:creator>Ye Zhang</dc:creator>
<dc:creator>Jian-Yuan Zhao</dc:creator>
<dc:creator>Hui Tao</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>SLC31A1 loss depletes mitochondrial copper and promotes cardiac fibrosis</dc:title>
<dc:identifier>pmid:40048660</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf130</dc:identifier>
</item>
<item>
<title>Missing 'lncs': how insufficient scrutiny can lead to misrepresentation of long non-coding RNAs (lncRNAs) and their function in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40048659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 6:ehaf115. doi: 10.1093/eurheartj/ehaf115. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40048659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40048659</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf115>10.1093/eurheartj/ehaf115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40048659</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew Bennett</dc:creator>
<dc:creator>Igor Ulitsky</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Missing 'lncs': how insufficient scrutiny can lead to misrepresentation of long non-coding RNAs (lncRNAs) and their function in cardiovascular disease</dc:title>
<dc:identifier>pmid:40048659</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf115</dc:identifier>
</item>
<item>
<title>LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 6. doi: 10.1161/CIRCRESAHA.124.325196. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Endothelial cell (EC) dysfunction and vascular inflammation are critical in the initiation and progression of atherosclerosis. Long noncoding RNAs play a critical role in vascular pathology, but relatively little is known about their involvement in controlling vascular inflammation. MIR181A1HG is a conserved long noncoding RNA located in juxtaposition with miR-181a1 and miR-181b1, both involved in vascular inflammation. The study aims to investigate the role of MIR181A1HG in regulating vascular inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined the expression of MIR181A1HG in both human and mouse atherosclerotic lesions. Loss-of-function and gain-of-function studies, and multiple RNA-protein interaction assays were used to investigate the role and molecular mechanisms of MIR181A1HG in vascular inflammation and atherosclerosis. The atherosclerotic phenotypes of MIR181A1HG<sup>-/-</sup>ApoE<sup>-/-</sup> mice were analyzed in combination with single-cell RNA sequencing. The transcriptional regulation of MIR181A1HG was verified through luciferase reporter and chromatin immunoprecipitation assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: MIR181A1HG expression was abundant in ECs and significantly increased in both human and mouse atherosclerotic lesions. MIR181A1HG<sup>-/-</sup>ApoE<sup>-/-</sup> mice had reduced NLRP (NLR family pyrin domain containing) 3 inflammasome signaling, EC activation, monocyte infiltration, and atherosclerotic lesion formation. Genetic deletion of MIR181A1HG in myeloid sells did not alter the progression of atherosclerosis. Single-cell RNA sequencing analysis revealed that MIR181A1HG deficiency reduced the proportion of immune cells and enriched anti-inflammation pathways in EC clusters in atherosclerotic lesions. In contrast, EC-specific MIR181A1HG overexpression promoted NLRP3 inflammasome signaling, EC activation, and atherosclerotic lesion formation, effects that were reversed by pharmacological inhibition of NLRP3 (MCC950). MIR181A1HG was transcriptionally activated via an NF-κB (nuclear factor kappa B)/p65-dependent pathway. Mechanistically, MIR181A1HG mediated these effects on regulating NLRP3 inflammasome and EC activation in part through decoying Foxp1 (forkhead box transcription factor 1) away from the promoters of target genes, which was independent of the miR-181a1/b1 cluster. Finally, EC-specific Foxp1 silencing reversed the antiatherosclerotic effect mediated by MIR181A1HG-deletion in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40047069</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325196>10.1161/CIRCRESAHA.124.325196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40047069</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Huaner Ni</dc:creator>
<dc:creator>Yulong Ge</dc:creator>
<dc:creator>Ying Zhuge</dc:creator>
<dc:creator>Xiaoqiang Liu</dc:creator>
<dc:creator>Hangwei Chen</dc:creator>
<dc:creator>Junyi Liu</dc:creator>
<dc:creator>Weifeng Li</dc:creator>
<dc:creator>Xiang Wang</dc:creator>
<dc:creator>Gu Shen</dc:creator>
<dc:creator>Qiuling Wang</dc:creator>
<dc:creator>Rulin Zhuang</dc:creator>
<dc:creator>Mark W Feinberg</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:40047069</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325196</dc:identifier>
</item>
<item>
<title>Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>Communication between multicellular organs is essential to propagate signals and coordinate their function. Over the past decade, the role of extracellular vesicles in the molecular communication between cells in both physiological and pathological settings has received much attention. Extracellular vesicles can shuttle proteins, lipids and nucleic acids (such as RNA) between cells, thus inducing an array of functional changes in the recipient cells. In this Review, we describe the different...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 5. doi: 10.1038/s41569-025-01141-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Communication between multicellular organs is essential to propagate signals and coordinate their function. Over the past decade, the role of extracellular vesicles in the molecular communication between cells in both physiological and pathological settings has received much attention. Extracellular vesicles can shuttle proteins, lipids and nucleic acids (such as RNA) between cells, thus inducing an array of functional changes in the recipient cells. In this Review, we describe the different extracellular vesicle subclasses and their heterogeneous nature, provide insights into extracellular vesicle-mediated signalling in the cardiovascular system, and highlight how extracellular vesicles can be used as diagnostic and prognostic biomarkers for a variety of pathological conditions. Finally, we also discuss the potential therapeutic applications of extracellular vesicles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40045042</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01141-2>10.1038/s41569-025-01141-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40045042</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Junjie Xiao</dc:creator>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy</dc:title>
<dc:identifier>pmid:40045042</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01141-2</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307212411&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):968-969. doi: 10.1016/j.jacc.2025.01.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307212411&v=2.18.0.post9+e462414">40044301</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.003>10.1016/j.jacc.2025.01.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044301</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:40044301</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.003</dc:identifier>
</item>





























</channel>
</rss>